MedTrace Logo

Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients

NCT04290429 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-11-29

No results posted yet for this study

Summary

In this study the investigators evaluate the outcomes of six steroid-refractory GVHD patients with gastrointestinal signs of GVHD that were treated with teduglutide.

Conditions

Interventions

DRUG

Teduglutide

Treatment of patients with SR-GI-GVHD with teduglutide

Sponsors & Collaborators

  • University of Freiburg

    lead OTHER

Principal Investigators

  • Robert Zeiser, Prof. Dr. · Medical Center University of Freiburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-06
Primary Completion
2019-12-06
Completion
2019-12-06

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04290429 on ClinicalTrials.gov